CPT and Smoking Cessation

VA Office of Research and Development

Status and phase: Completed; Phase 3; Phase 2

Conditions: Stress Disorders, Post-Traumatic; Smoking

Treatments: Behavioral: smokefreeVET; Drug: nicotine replacement therapy (NRT); Behavioral: Integrated Care for Smoking Cessation (ICSC); Behavioral: Cognitive Processing Therapy (CPT); Drug: Bupropion

Study type: Interventional

Funder types: Other U.S. Federal agency

Identifiers

NCT01901848

MHBA-018-12F

Details and patient eligibility

About

Posttraumatic stress disorder (PTSD) and cigarette smoking are both associated with significant impairment in Veterans and cost to the Veterans' Affairs (VA) system. Though research suggests smoking is linked with PTSD symptoms, existing smoking cessation treatments targeting PTSD smokers do not include PTSD treatment. The purpose of this study is to examine a treatment that combines evidence based treatment for PTSD (cognitive processing therapy, or CPT) with smoking cessation treatment for PTSD and a mobile text messaging program. The study objectives are to evaluate feasibility of the treatment and to examine effectiveness of CPT and smoking cessation treatment combined compared to smoking cessation treatment without CPT. Fifty Veteran smokers with PTSD will participate in fourteen study sessions, ending with the final follow-up session six months after the scheduled quit date.

Full description

Posttraumatic stress disorder (PTSD) and cigarette smoking are both associated with significant impairment in Veterans and cost to the Veterans' Affairs (VA) system. Though naturalistic and laboratory studies suggest smoking is linked with PTSD symptoms, existing smoking cessation treatments targeting PTSD smokers have not utilized standardized, evidence-based PTSD treatment. The most effective smoking cessation approach to date for PTSD smokers, Integrated Care for Smoking Cessation (ICSC), relies on delivery of smoking cessation treatment by the individual's PTSD treatment provider. In a recent trial comparing ICSC to VA specialty Smoking Cessation Clinic care, ICSC produced significantly better prolonged smoking abstinence. However, ICSC was associated with only modest improvements in PTSD symptoms, with no difference between ICSC and smoking cessation treatment alone, suggesting a likely avenue for improving ICSC. The investigators have developed an intervention that combines evidence based treatment for PTSD [cognitive processing therapy (CPT-C)] with evidence based smoking cessation for PTSD [Integrated Care for Smoking Cessation (ICSC)] and a mobile text messaging program. The primary aim of the proposed study is to evaluate the integration of CPT-C and smoking cessation treatment in an individual 12-session PTSD protocol as compared to a protocol including the same smoking cessation treatment for individuals with PTSD, but without CPT-C. This intervention will be evaluated with the following hypotheses:

1. Compared to the smoking cessation alone protocol, the smoking cessation + concurrent CPT-C protocol will result in reduced frequency and intensity of PTSD symptoms.
2. Compared to the smoking cessation alone protocol, the smoking cessation + concurrent CPT-C protocol will result in reduced depressive symptoms.
3. The smoking cessation + concurrent CPT-C protocol will result in decreased smoking rates, relative to published data on VA smoking cessation usual care.
4. Greater PTSD symptom reduction during the smoking cessation + concurrent CPT-C treatment will result in longer duration to smoking lapse and relapse.
5. Exploratory research question: Will candidate genes described earlier predict treatment response in smokers with PTSD?
6. Exploratory research question: Will use of automated text messaging as an adjunct to smoking cessation be feasible, and will it impact quit rates?

The development of a combined CPT-C/ICSC intervention with established empirical support would benefit the many Veterans with PTSD who smoke by providing them with treatment of two pervasive problems with significant associated impairment. In addition, this treatment could substantially reduce the cost of administering two individual treatments separately by administering them in combination.

Enrollment: 69 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must be U.S. Veteran
• Smoke at least ten cigarettes a day
• Meet criteria for current PTSD
• Speak and write fluent conversational English
• Be between 18 and 65 years of age
• Be willing to attempt smoking cessation
• Must have access to a phone capable of receiving text messages

Exclusion criteria

• Not stable on medications for the study period
• History of myocardial infarction in the past 6 months
• Contraindication to NRT and inability to get medical clearance from primary care provider
• Use of other forms of nicotine such as cigars, pipes, or chewing tobacco.
• Pregnancy
• Inability to complete study measures and tasks independently
• Dementia or other brain disorder, schizophrenia, current manic syndrome, or substance abuse/dependence in the preceding 3 months.
• Currently receiving trauma-focused psychotherapy.
• Currently living in court-ordered residential substance abuse treatment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

69 participants in 2 patient groups

CPT+ICSC

Experimental group

Description:

This arm includes 12 sessions of combined Cognitive Processing Therapy (CPT) and Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.

Treatment:

Drug: Bupropion

Behavioral: Integrated Care for Smoking Cessation (ICSC)

Behavioral: Cognitive Processing Therapy (CPT)

Behavioral: smokefreeVET

Drug: nicotine replacement therapy (NRT)

ICSC only

Active Comparator group

Description:

This arm includes 12 sessions of Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.

Treatment:

Drug: Bupropion

Behavioral: Integrated Care for Smoking Cessation (ICSC)

Behavioral: smokefreeVET

Drug: nicotine replacement therapy (NRT)